|Conversion of human fibroblasts to angioblast-like progenitor cells.|
|Jump to Full Text|
|PMID: 23202434 Owner: NLM Status: MEDLINE|
|Lineage conversion of one somatic cell type to another is an attractive approach for generating specific human cell types. Lineage conversion can be direct, in the absence of proliferation and multipotent progenitor generation, or indirect, by the generation of expandable multipotent progenitor states. We report the development of a reprogramming methodology in which cells transition through a plastic intermediate state, induced by brief exposure to reprogramming factors, followed by differentiation. We use this approach to convert human fibroblasts to mesodermal progenitor cells, including by non-integrative approaches. These progenitor cells demonstrated bipotent differentiation potential and could generate endothelial and smooth muscle lineages. Differentiated endothelial cells exhibited neo-angiogenesis and anastomosis in vivo. This methodology for indirect lineage conversion to angioblast-like cells adds to the armamentarium of reprogramming approaches aimed at the study and treatment of ischemic pathologies.|
|Leo Kurian; Ignacio Sancho-Martinez; Emmanuel Nivet; Aitor Aguirre; Krystal Moon; Caroline Pendaries; Cecile Volle-Challier; Francoise Bono; Jean-Marc Herbert; Julian Pulecio; Yun Xia; Mo Li; Nuria Montserrat; Sergio Ruiz; Ilir Dubova; Concepcion Rodriguez; Ahmet M Denli; Francesca S Boscolo; Rathi D Thiagarajan; Fred H Gage; Jeanne F Loring; Louise C Laurent; Juan Carlos Izpisua Belmonte|
Related Documents :
|24691114 - Opposing effects of smoking in ulcerative colitis and crohn's disease may be explained ...
24155454 - Primary central nervous system t-cell lymphoma mimicking meningoencephalomyelitis in a ...
23126274 - Detection of the gd2+/cd56+/cd45- immunophenotype by flow cytometry in cerebrospinal fl...
23762264 - Platelet-rich plasma promotes the proliferation of human muscle derived progenitor cell...
22536454 - Spermatogonial stem cells (sscs) in buffalo (bubalus bubalis) testis.
21731674 - An information theoretic, microfluidic-based single cell analysis permits identificatio...
|Type: Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S. Date: 2012-12-02|
|Title: Nature methods Volume: 10 ISSN: 1548-7105 ISO Abbreviation: Nat. Methods Publication Date: 2013 Jan|
|Created Date: 2012-12-27 Completed Date: 2013-04-09 Revised Date: 2013-07-11|
Medline Journal Info:
|Nlm Unique ID: 101215604 Medline TA: Nat Methods Country: United States|
|Languages: eng Pagination: 77-83 Citation Subset: IM|
|Gene Expression Laboratory, Salk Institute for Biological Studies, La Jolla, California, USA.|
|Data Bank Information|
Bank Name/Acc. No.:
|APA/MLA Format Download EndNote Download BibTex|
Biological Markers / metabolism
Endothelium, Vascular / cytology*, metabolism
Fibroblasts / cytology*, metabolism
Fluorescent Antibody Technique
Myocytes, Smooth Muscle / cytology*, metabolism
RNA, Messenger / genetics
Real-Time Polymerase Chain Reaction
Reverse Transcriptase Polymerase Chain Reaction
Stem Cells / cytology*, metabolism
|R33 MH087925/MH/NIMH NIH HHS; R33MH087925/MH/NIMH NIH HHS|
|0/Biological Markers; 0/RNA, Messenger|
|Nat Methods. 2013 Jan;10(1):44-5
Journal ID (nlm-journal-id): 101215604
Journal ID (pubmed-jr-id): 32338
Journal ID (nlm-ta): Nat Methods
Journal ID (iso-abbrev): Nat. Methods
nihms-submitted publication date: Day: 14 Month: 11 Year: 2012
Electronic publication date: Day: 02 Month: 12 Year: 2012
Print publication date: Month: 1 Year: 2013
pmc-release publication date: Day: 01 Month: 7 Year: 2013
Volume: 10 Issue: 1
First Page: 77 Last Page: 83
PubMed Id: 23202434
|Conversion of human fibroblasts into angioblast-like multipotent progenitor cells|
|Ahmet M. Denli4|
|Francesca S. Boscolo5|
|Rathi D. Thiagarajan5|
|Fred H. Gage4|
|Jeanne F. Loring56|
|Louise C. Laurent57|
|Juan Carlos Izpisua Belmonte13|
1Gene Expression Laboratory, Salk Institute for Biological Studies, 10010 North Torrey Pines Road, La Jolla, CA 92037 USA
2Sanofi-Aventis R&D, E2C, 195 Route d’fEspagne, Toulouse Cedex 31636, France
3Center of Regenerative Medicine in Barcelona, Dr. Aiguader, 88, 08003 Barcelona, Spain
4Laboratory of Genetics, Salk Institute for Biological Studies, 10010 North Torrey Pines Road, La Jolla, CA 92037 USA
5Department of Chemical Physiology, The Scripps Research Institute, La Jolla, CA 92037, USA
6Center for Regenerative Medicine, The Scripps Research Institute, La Jolla, CA 92037, USA
7Department of Reproductive Medicine, University of California, La Jolla, CA 92093, USA
|Correspondence: Author for correspondence: Juan Carlos Izpisua Belmonte, email@example.com; firstname.lastname@example.org
*These authors contributed equally to this work
Somatic cell reprogramming has highlighted the high plasticity of adult somatic cells as well as the possibility of generating any desired cell type in unlimited amounts. Based on the forced expression of selected transcription factors (TFs), three major different approaches allowing for somatic cell reprogramming have recently been described1. First, somatic cells can be reprogrammed into induced Pluripotent Stem Cells (iPSCs), embryonic-like cells with the potential, upon further differentiation, to generate all different cell-types present in the adult organism2. Second, the concept of TFs defining or specifying target cell identity has proven successful for the direct lineage conversion of mouse and human cells into a number of different cell types3–6. Finally, the fact that reprogramming leading to iPSC formation proceeds in a step-wise de-differentiation manner suggests that this process can be controlled and stopped prior to the acquisition of an embryonic-like signature. Indeed, coupling a partially de-differentiated plastic state to specific differentiation conditions has demonstrated a feasible alternative way to generate murine cardiac and neuronal cells7–11.
In here we present the development of a simple and highly efficient method allowing for the conversion of human fibroblasts into CD34+ progenitor cells with bi-potent differentiation potential. The process of conversion occurs indirectly by shortening and/or bypassing complete reprogramming to pluripotency while allowing for the generation of a “plastic” state. Transitioning through a plastic intermediate state allowed for re-differentiation into CD34+ progenitor cells and subsequently, further differentiation to functional endothelial and smooth muscle lineages.
We speculated that coupling a robust differentiation protocol to partially reprogrammed cells could provide a suitable platform for cell fate conversion. As such, we developed a robust media suitable for the differentiation of pluripotent stem cells (PSCs) to mesodermal progenitor cells prior to establishing the reprogramming conditions necessary for cell-fate conversion. Thus, we systematically analyzed different well-known mediators of mesodermal development in different human PSC (hPSC) lines12. We found that a media, hereafter referred to as Mesodermal Induction Media or MIM, containing DMEM:F12, 15 mg ml−1 stem cell grade BSA, 17.5 μg ml−1 Human Insulin, 275 μg ml−1 Human holo-transferrin, 20 ng ml−1 bFGF, 50 ng ml−1 Human VEGF, 25 ng ml−1 human BMP4, 450 μM monothioglycerol and 2.25 mM L-Glutamine and Non-essential amino acids, but in the absence of Activin-A, was highly efficient in driving hPSCs to a mesodermal fate (Fig. 1a and Supplementary Fig. 1). Next, we tested MIM differentiation on multiple human PSC lines by focusing on CD34 expression, an early marker for mesoderm-derived progenitor cells with hematopoietic and/or endothelial and smooth muscle differentiation potential (Fig. 1b–f and Supplementary Fig. 1–2). A peak of CD34+ cells was observed by day 8 in every analyzed cell line. In parallel, we observed upregulation of the vascular marker CD31 (Fig. 1b–f and Supplementary Fig. 1–2) accompanied by rapid downregulation of pluripotency-related markers (Fig. 1g and Supplementary Fig. 2). Similarly, expression of mesodermal progenitor markers was significantly upregulated (Fig. 1b–g and Supplementary Fig. 1–2). Additionally, we observed the upregulation of several early markers related to hematopoiesis, including RUNX1 and SCL/TAL1 (Supplementary Fig. 2). Thus, MIM might lead to the generation of a tri-potent hemangioblast-like state with hematopoietic, endothelial and smooth muscle differentiation potential. MIM-differentiated PSC-derived CD34+ cells (PSCCD34+) did not result in the expression of any hematopoietic marker analyzed at the protein level or the formation of hematopoietic colonies in standard hematopoietic Colony Forming Assays.
We next wondered whether MIM-induced CD34+ cells represented a developmental stage similar to that of angioblast cells13 by investigating the potential of PSCCD34+ cells to differentiate into endothelial and smooth muscle lineages. Sorting of 8 days MIM- differentiated PSCCD34+ cells and subsequent differentiation towards the endothelial lineage gave rise to endoglin and VE-cadherin positive endothelial cells (Fig. 1h and Supplementary Fig. 3). Importantly, expression of von Willebrand factor (vWF), a mature endothelial marker and pro-coagulant protein additionally playing a role in wound healing and vessel repair, was readily detected (Fig. 1h and Supplementary Fig. 3). Two-step differentiation of PSCs by inducing mesoderm commitment and subsequent differentiation of CD34+ cells towards the endothelial lineage, gave rise to 60–90% VE-cadherin+ endoglin+ cells in all cell lines analyzed. qPCR analysis of PSC-differentiated endothelial cells demonstrated significant upregulation of endothelial markers whereas no upregulation was observed for smooth muscle markers (Fig. 1i and Supplementary Fig. 3); thus, indicating specificity of differentiation towards the endothelial lineage.
Similarly, PSCCD34+ cells were sorted and subjected to smooth muscle differentiation conditions. Differentiation of isolated progenitors yielded a high number of smooth muscle cells (Supplementary Fig. 4). mRNA analysis demonstrated significant upregulation of smooth muscle markers, including expression of the smooth muscle-specific high molecular weight Caldesmon type 1 (CALD1), while no endothelial marker was upregulated (Supplementary Fig. 4). Single cell differentiation assays demonstrated the multipotent nature of the generated cells (Supplementary Fig. 4). Next, we performed genome-wide DNA methylation and gene expression studies. As expected there was a clear distinction between all of the differentiated samples and the undifferentiated PSCs at both, the transcriptome as well as the methylome level (Fig. 1j, k and Supplementary Fig. 5). Few unique differences between PSC-endothelial differentiated cells and primary endothelial cells were found. Similarly, there was a clear distinction between all of the differentiated smooth muscle samples as compared to undifferentiated PSCs (Supplementary Fig. 6).
In summary, our studies identify a novel chemically defined media (MIM) leading to the generation of CD34+ progenitor cells in a more efficient manner than previously described protocols14–16. MIM differentiation was sufficient for the generation of PSCCD34+ cells with the potential to generate both endothelial and smooth muscle lineages. Thus, MIM differentiation of PSCs results in the generation of a progenitor population resembling an angioblast-like state.
We next asked whether MIM could suffice for the conversion of human fibroblasts into CD34+ angioblast-like progenitor cells (FibCD34+). Thus, we decided to couple a first phase of “plastic” induction or de-differentiation by short-term exposure to iPSC reprogramming conditions7,8, followed by MIM differentiation (Fig. 2a). First, we explored the suitability of this conversion process by retroviral approaches and the traditional four-factor combination, including SOX2, Oct4, KLF4 and c-Myc, in two different lines of neonatal (HFF and BJ) as well as adult human dermal fibroblasts (HDF). 8-day exposure of human fibroblasts to reprogramming factors and iPSC-like culture conditions coupled to MIM differentiation for an additional 8-day period led to the appearance of a prominent FibCD34+ population (Fig. 2b, c). Additionally, we asked whether the miR 302–367 clusters, demonstrated to play a role during reprogramming towards iPSCs17,18, could lead to increasing efficiencies of FibCD34+ cell generation. miR 302–367 seemed to contribute to the conversion of human fibroblasts in some but not all lines analyzed (Fig. 2c and Supplementary Fig. 7). MIM differentiation led to a significant upregulation of angioblast-related markers in all conditions analyzed (Fig. 2d). Sorting of MIM-differentiated FibCD34+ cells and subsequent differentiation into endothelial and smooth muscle cells resulted in the upregulation of lineage-specific markers at both the RNA and protein levels (Fig. 2e, f and Supplementary Fig. 7). We next sought to determine the minimal combination of factor(s) required for the conversion of human fibroblasts into FibCD34+ by systematic single factor removal. Marginal levels of CD34+ cells were found when SOX2 was employed alone. Yet, subsequent differentiation of sorted SOX2-generated CD34+ cells did not result in the generation of endothelial nor smooth muscle cells. Altogether, the four Yamanaka factors, alongside the use of iPSC-like culture conditions, seemed indispensable for the conversion, into FibCD34+ with bi-potent differentiation potential resembling that of an angioblast-like state.
Similarly to PSC differentiation, cell fate conversion of human fibroblasts towards the endothelial lineage resulted in a mixture of different endothelial sub-types, including the expression of arterial, venous and lymphatic endothelial markers19 (Supplementary Fig. 8). Along the same line, analysis of human fibroblasts converted to smooth muscle cell populations demonstrated mixed expression of smooth muscle markers20 including expression of the pericyte marker NG2 (Supplementary Fig. 9). Of relevance, the converted endothelial cells had lost many features of the fibroblast profile and acquired characteristics of primary endothelial cells (Fig. 2g and Supplementary Fig. 5). Converted endothelial cells also lost their fibroblast epigenetic signature and acquired a DNA methylation profile that closely resembled that of primary endothelial cells (Fig. 2h and Supplementary Fig. 5). When all samples were compared, regardless of their method of derivation, fibroblasts formed a third major group in the differentiated portion of the dendograms, slightly closer to the primary and PSC-differentiated endothelial cell clusters as compared to converted endothelial cells, which clustered more closely to iPSC-differentiated cells. Interestingly, both, the mRNA expression and DNA methylation results were very similar in terms of describing the relationships among all different cell types (Supplementary Fig. 5 and 6).
Altogether, our results demonstrate that 8-day exposure to iPSC reprogramming factors and culture conditions was sufficient for the induction of an intermediate plastic state in human fibroblasts. Further mesodermal induction by 8-day exposure to MIM yielded intermediate CD34+ bi-potent progenitor populations, which ultimately led to the generation of both endothelial and smooth muscle cell populations. Whereas expandable populations, alongside the lack of clonal expansion and colony formation, made precise frequency analysis technically difficult,“angioblast conversion efficiencies” could be calculated by estimating the ratio between the final number of converted cells and the initial number of fibroblasts. Taking into account that 75,000 fibroblasts give rise to ~2×106 cells by the end of MIM commitment, of which 20–60% are CD34+ (depending on the cell line of origin and the method used for plasticity induction), conversion efficiencies would range between 400–1200%. Altogether, human fibroblasts were subjected to three different steps during the process of conversion: first, a controlled phase of reprogramming totaling 8 days; second, specification of the generated reprogrammed intermediates to mesodermal FibCD34+ progenitor cells by MIM; lastly, further differentiation of the generated FibCD34+ cells to endothelial and smooth muscle cells.
We next wondered whether the process of conversion could result in an iPSC-like stage even in the absence of visible flattened ES-like colonies. We focused on TRA1-81 and TRA1-60 expression as the latter has been recently described as the most reliable early marker for iPSC generation, with a success prediction rate of up to 90%21. Plastic induction did not lead to the expression of either TRA1-60 or TRA1-81 (Fig. 2b and Supplementary Fig. 10).
Noticeably, residual expression of the transgenes was still detectable upon differentiation (Supplementary Fig. 10). In view of these results as well as the possibility for re-activation of integrated oncogenes, we next pursued the establishment of non-integrative approaches. To this end we evaluated an episomal vector combination proven to allow for the generation of human iPSCs in the presence of murine feeder layers22. A six-factor combination including Oct4, SOX2, KLF4 and non-transforming LMYC (MYCL1) alongside shRNA-p53 and LIN28 was chosen for further experiments (Fig. 3). Plastic reprogramming intermediates were obtained by electroporation of 1.5 μg of DNA from each of the vectors followed by a 6-day resting phase prior to switching to iPSC-like reprogramming conditions (Fig. 3a). After 8 days, the media was changed to MIM, for an additional 8 days resulting, in the appearance of CD34+ cells whereas expression of TRA1-60 and TRA1-81 remained undetectable (Fig. 3b, c). Sorting of FibCD34+ cells and subsequent differentiation into endothelial and smooth muscle lineages resulted in the upregulation of cell-type specific markers at both the RNA and protein level (Fig. 3d–g). The generated endothelial and smooth muscle cells represented mixed populations of different sub-types similar to the results obtained by differentiation of PSCs (Fig. 3g).
Most importantly, we observed the rapid clearing of the episomal vectors and no random integration of exogenous genes was detected in the differentiated endothelial cells (Supplementary Fig. 10). Furthermore, testis injection of one million differentiated endothelial cells did not result in teratoma formation in any of the groups analyzed after 10 weeks, including cells generated by differentiation of PSCs (Supplementary Fig. 10).
Two well-characterized physiological hallmarks of smooth muscle cell function are their calcium responses as well as cell contraction capabilities20,23,24. Contraction of differentiated smooth muscle cells occurred both spontaneously as well as upon drug stimulation (Supplementary Fig. 11 and Supplementary Video 1). Exposure to carbachol resulted in rapid Calcium transients. Of note, whereas we did observe a response of 293T human embryonic kidney cells to carbachol, this response was limited to calcium transients and did not result in the physical contraction of the cells as demonstrated by their unchanged cell surface area (Supplementary Fig. 11). We next investigated the functionality of the generated endothelial cells by measuring their acetylated-LDL uptake, a characteristic of mature endothelial cells. CD34+-derived endothelial cells showed significantly higher rates of LDL uptake as compared to their respective negative controls (Fig. 3h and Supplementary Fig. 12). Noticeably, differentiated endothelial cells aggregated into vessel-like structures in vitro and were able to form functional vessels, allowing for blood circulation, after 17 days in vivo (Fig. 3i, 4 and Supplementary Fig. 12). Thus, demonstrating connection of the newly formed vessels to the pre-existing vasculature. Endothelial cell identity was verified by Ulex-lectin binding and the human origin of the cells further verified by in situ hybridization (Fig. 4b, c) as well as the use of antibodies specific for human CD31 and co-localization with the human nuclear antigen (Fig. 4d, e).
Altogether our results demonstrate that the use of chemically defined MIM media allowed for the commitment of plastic reprogramming intermediates to an angioblast-like fate. Further differentiation of angioblast-like cells resulted in the generation of functional endothelial and smooth muscle cells. Most importantly, 8-day reprogramming coupled to subsequent MIM differentiation for another 8 days was sufficient to drive the conversion of both neonatal and adult human fibroblasts to angioblast-like progenitor cells while bypassing iPSC generation. Lastly, PSC-derived as well as converted CD34+-derived endothelial cells demonstrated functionality in vitro and contributed to the vasculature in vivo.
We have established an efficient method for the conversion of human fibroblasts into CD34+ angioblast-like progenitor cells (Supplementary Table 1). These cells could be further differentiated into functional endothelial and smooth muscle cells. Interestingly, we observed certain differences at both the transcriptome and methylome level when compared to the positive controls. One possible explanation could reside in the unspecific nature of the generated endothelial and smooth muscle populations, including different sub-types of each respective major lineage as compared to the primary cells analyzed (Human Umbilical Vein Endothelial Cells and Arterial Smooth Muscle Cells). Another explanation could be reminescent to the epi/genetic differences found when comparing iPSCs versus ESCs, their respective positive “control”, as well as when comparing different ESC clones25. Lastly, residual epigenetic marks from the initial fibroblast cells might also account for the observed differences6. Nevertheless, all the cells generated (either differentiated from PSCs or derived by conversion of human fibroblasts) demonstrated functional properties, thus, highlighting the potential of these novel conversion methodologies as well as the importance of analyzing functional parameters in reprogramming paradigms6,25,26.
Conversion into angioblast-like progenitor cells occurred in the absence of iPSC colony formation, surface marker expression and re-activation of the endogenous transcription network regulating pluripotency, therefore shortening considerably the time required for generation of the desired cell types. Whereas the current measures do not permit us to rule out that converted cells transitioned through a somewhat “pluripotent-like” state, the lack of pluripotent marker expression and teratoma formation indicates that the conversion process does not result in the typical iPSC features. Furthermore, the fact that induction of “plasticity” relies on a first phase of epigenetic erasure, which by similarity with iPSC reprogramming might imply a stochastic process, strongly suggests that the heterogeneity observed at the molecular level during the conversion process might be due to the presence of cells with varying degrees of epigenomic plasticity. The present study represents the first demonstration that short-term induction by iPSC reprogramming conditions, followed by exposure to a chemically defined differentiation media, is sufficient for the conversion of neonatal and adult human fibroblasts into angioblast-like progenitor cells. Of note, not only the autonomous effects of the reprogramming factors but the overall combination of stem cell culture conditions promoting cell proliferation, as exemplified by the requirement of bFGF, have demonstrated to be crucial during the process of conversion in a similar way to iPSC reprogramming. Interestingly, culture conditions have also been highlighted as a critical component during the conversion process in similar reports7,8. Contrary to direct lineage conversion, that requires precise knowledge and screening of molecules defining target cell identity, induction of “plastic/de-differentiation” states coupled to specific differentiation protocols might provide a general, more readily accessible, platform towards the broader generation of clinically relevant cell types. Furthermore, whereas direct lineage conversion might be viewed as an “unnatural” process6 occurring in the absence of progenitor cell generation, our results and those reported for the murine system7,8 show, as during normal embryogenesis, the formation of intermediate progenitor states. Therefore, whereas direct lineage conversion occurs in one-to-one basics in the absence of progenitor cell generation and cell proliferation, transition through a proliferative progenitor state may have two major practical implications. On the one hand the generation of progenitor cells with multilineage differentiation capacity strongly diversifies the spectra of applications as opposed to direct lineage conversion. On the other hand, the inability to generate proliferative populations by direct lineage conversion could represent a major limitation for applications in which large numbers of cells are required6,9. Of note, in the case shown here, the conversion of human fibroblasts into vascular smooth muscle and endothelial cells proceeds through the generation of an expandable population of vascular progenitors with multilineage differentiation capacity. Altogether, our results describe a novel methodology for the reprogramming of somatic cells and provide a complementary approach to those of direct lineage conversion and iPSCs methodologies for the generation of specific human cell types.
The following antibodies were used at the specified concentrations: mouse anti-human CD34-APC 1:10 (130–046–703, Miltenyi), mouse anti-human CD133/2 (293C3)-PE 1:10 (130–090–853, Miltenyi), mouse anti-human CD144-PE 1:10 (VE-cadherin; 560410, BD biosciences), mouse anti-human CD144-APC 1:10 (VE-cadherin; 348507, Biolegend), CD105-PE 1:10 (endoglin; ab60902, Abcam), mouse anti-human CD105-PE 1:10 (endoglin; 560839, BD biosciences), CD31-FITC 1:10 (555445, BD biosciences), CD117-PeCy7 1:10 (c-Kit; 339195, BD biosciences), VEGFR2-PE 1:10 (KDR; 560494, BD biosciences), mouse anti-human CD45-FITC 1:10 (130–080–202, Miltenyi), anti-human CD235a-PE 1:10 (340947, BD biosciences), mouse APC isotype control 1:10 (555751, BD biosciences), mouse FITC isotype control 1:10 (555748, BD biosciences), PeCy7 isotype control 1:10 (557872, BD biosciences), PE isotype control 1:10 (555749, BD biosciences), VE-Cadherin 1:500 (555661, BD biosciences), Endoglin 1:500 (M3527, DAKO), Anti-von Willebrand Factor 1:200 (vWF; 7356, Millipore), calponin 1:500 (Dako, M3556), α-SMA 1:500 (AB56994, Abcam), α-SMA 1:1000 (A5228, Sigma), PECAM-1 (M-20) 1:100 (CD31; sc1506, Santa Cruz Biotechnology) anti-Human Nuclei 1:100 (MAB1281, Millipore), DAPI [5 mg ml−1] 1:2000 (D1306, Invitrogen), Hoechst 33342 [5mg ml−1] 1:2000 (B2261, Sigma), Alexa fluor 488 goat anti-mouse (A11001, Invitrogen), Alexa fluor 488 Donkey anti-goat (A11055, Invitrogen), Alexa fluor 568 Donkey anti-mouse (A10037, Invitrogen), Alexa-fluor 568 Donkey anti-rabbit (A10042, Invitrogen).
Human ES cells, H1 (WA1, WiCell), HuES 9 (http://www.mcb.harvard.edu/melton/hues/) and Human iPS cells CBiPS27 and KiPS28 (KIPS 4F#2, CBiPS 2F#4) (passage 25–45) were cultured in chemically defined hES/hiPS growth media (mTeSR29 on growth factor reduced matrigel (35623, BD biosciences) coated plates). Briefly, 70–80% confluent hES/iPS cells were treated with dispase (Invitrogen) for 7 minutes at 37°C, colonies were dispersed to small clusters and lifted carefully using a 5 ml glass pipette, at a ratio of ~1:4. Neonatal human fibroblasts (HFF-1, BJ; ATCC) and adult human dermal fibroblasts (HDF-693) were cultured in DMEM containing 10% FBS, 2 mM GlutaMAX (Invitrogen), 50 U ml−1 penicillin and 50 mg ml−1 streptomycin (Invitrogen). Human Umbilical Vein Endothelial Cells (HUVEC) were purchased from Promocell and cultured in EBM medium supplemented with EGM-2 singlequots (cc-3162, Lonza), 2% FBS, hEGF 10 μg ml−1, Heparin 100 μg ml−1 (Sigma). iPS/ES-derived endothelial cells were cultivated in EBM-2 medium supplemented with EGM-2 singleQuot kit (cc-3162, Lonza). iPS/ES-derived smooth muscle cells were cultured in SmBM medium supplemented with SmGM-2 singleQuot kit (cc-3182, Lonza). All the cells were grown in collagen I coated plates (BD biosciences). All cell lines were maintained in an incubator (37°C, 5% CO2) with media changes every day (hES/iPS) or every second day (HUVEC/Fibroblasts).
Human ES/iPS cells cultured as described above were freshly split on matrigel-coated plates, making sure the sub-colonies were of small size (~300–500 cells/colony). After 24 hours of recovery in mTeSR, the cells were gently washed using DMEM:F12 (Invitrogen) and allowed to grow in chemically defined differentiation media (Mesodermal Induction Media or MIM), which consists of DMEM:F12, 15 mg ml−1 stem cell grade BSA (MP biomedicals), 17.5 μg ml−1 Human Insulin (SAFC bioscience), 275 μg ml−1 Human holo-transferrin (Sigma Aldrich), 20 ng ml−1 bFGF (Stemgent), 50 ng ml−1 Human VEGF-165 aa (Humanzyme), 25 ng ml−1 human BMP4 (Stemgent), 450 μM monothioglycerol (Sigma Aldrich), 2.25 mM each L-Glutamine and Non-essential amino acids (Invitrogen), systematically designed by titration of growth factors and culture conditions. Media was changed every second day with addition of half the volume of media every other day.
Upon MIM differentiation for 8 days, CD34+ Angioblast-like cells (Angioblast-like) were sorted and plated in collagen I coated 48-well plates at a density of one cell/well in either EBM-2 (endothelial differentiation) or SmBM (Smooth Muscle differentiation) supplemented as described above. After 7 days in the respective differentiation conditions cells were washed once with PBS and fixed with 4% Paraformaldehyde (PFA) in 1X PBS. Following fixation, cells were blocked and permeabilized for 1 hour at 37° C with 5% BSA/5% appropriate serum/1X PBS in the presence of 0.1% Triton X100. Subsequently, cells were incubated overnight at 4° C with an anti-endoglin antibody in case of cells in EBM-2/EGM-2 or with an anti-calponin antibody in the case of cells in SmBM/SmGM-2. Cells were then washed thrice with 1X PBS, incubated for 1 hour at 37° C with the respective secondary antibodies and 20 minutes with DAPI for nuclear staining. Following incubation, cells were washed thrice with 1X PBS before microscopy analysis and scoring.
For retroviral infection, 75,000/well human fibroblast cells (HFF-1, BJ, HFF-693) were plated on matrigel-coated 6-well plates. The next day, cells were infected with an equal ratio of either a combination of 4 pMX-derived retroviruses encoding Oct4, SOX2, KLF4 and c-Myc (4F) or 5 pMX-derived retroviruses encoding Oct4, SOX2, KLF4, c-Myc and miRs302–367 (4F/miRs). Scramble miRNA control (PMIRH000PA-1, SBI) was used whenever appropriate. The plates were infected by spinfection of the cells at 1850 rpm for 1 hour at room temperature in the presence of polybrene (4 μg ml−1) and put back in the incubator without media change. 24 hours later, the media was switched to WiCell media composed of DMEM/F12 (Invitrogen), 20% Knockout serum replacement, 10 ng ml−1 bFGF, 1 mM GlutaMax, 0.1 mM non-essential amino acids and 55 μM β-mercaptoethanol; with media changes every day. After 6 days, cells were split at a ratio of 1:3 on to matrigel coated 6-well plates supplemented with WiCell media for another 2 days. The cells were then washed once with DMEM/F12 and induced for differentiation for 8 days in the presence of MIM. Media was changed every second day with addition of half the volume of media every other day.
For episomal transfection, 2.106 cells were transfected with 1.5μg each of pCXLE-episomal vectors encoding for Oct4, SOX2, KLF4, LMYC, LIN28 and shRNA-p5322 (#27077, #27078 and #27080, addgene) with and without addition of pcDNA3.1 encoding for miRs302–367 (6F or 6F/miRs). Fibroblasts were transfected by nucleofection (Amaxa NHDF nucleofector kit, # VPD-1001) according to manufacturer’s instructions, and plated back on to matrigel-coated wells. After 6 days resting in DMEM/F12 supplemented with 10% FBS, 0.1 mM non-essential amino acids and 2 mM GlutaMAX, the media was switched to WiCell media with media changes every day. After 6 days, cells were split at a ratio of 1:3 on to matrigel coated 6-well plates with WiCell media for another 2 days. The cells were then washed once with DMEM:F12 and induced for differentiation for 8 days in the presence of MIM. Media was changed every second day with addition of half the volume of media every other day.
Total cellular RNA was isolated using Trizol Reagent (Invitrogen) according to the manufacturer’s recommendations. 2μg of DNAse1 (Invitrogen) treated total RNA was used for cDNA synthesis using the SuperScript II Reverse Transcriptase kit for RT-PCR (Invitrogen). Real-time PCR was performed using the SYBR-Green PCR Master mix (Applied Biosystems). The levels of expression of respective genes were normalized to corresponding GAPDH values and are shown as fold change relative to the value of the control sample. All the samples were done in triplicate. The list of the primers used for real time-PCR experiments are listed in Supplementary Table 3.
Human ES/iPS cells undergoing directed differentiation, lineage converted CD34+ cells or their respectively derived endothelial cells were harvested using TripLE (Invitrogen), washed once with PBS and further incubated with the corresponding antibodies in the presence of FACS blocking buffer (1xPBS/10%FCS) for 1 hour on ice in the absence of light. After incubation, cells were washed thrice with 1 ml of FACS blocking buffer and resuspended in a total volume of 200 μl prior to analysis. A minimum of 10,000 cells in the living population were analyzed by using a BD LSRII flow cytometry machine equipped with 5 different lasers and the BD FACSDiva software. Percentages are presented after subtracting isotype background and referring to the total living population analyzed. Results are representative of at least three independent experiments with a minimum of two technical replicates per experiment.
After 8 days of differentiation CD34+ cells were stained as described above and sorted by using a BDAria II FACS sorter (BD Biosystems). Alternatively, CD34+ cells were enriched using anti-CD34 conjugated magnetic beads (Miltenyi) according to the manufacturer’s instructions with slight modifications. Briefly, up to 109 cells were incubated with constant mixing at 4°C with 100 μl of the corresponding magnetic beads in the presence of 100 μl of Fc-blocking solution in a total volume of 500 μl FACS blocking buffer. After 1 hour, cells were sorted by two consecutive rounds of column separation in order to increase purity by applying MACS separation magnets. Shortly, cells were passed through the first MS separation column allowing binding of labeled cells. Non-labeled cells were washed thoroughly with 3 ml FACS blocking buffer prior to elution of the labeled fraction. Eluted labeled cells were then subjected to a second purification step as described above.
PSC- and lineage converted-CD34+ cells, isolated by MACS or by FACS sorting after 8 days of differentiation in MIM, were plated in collagen I coated plates (50,000 cells well−1 of a 12 well plate) and cultured in EBM-2/EGM-2 (Lonza) with media changes every day. After 5–8 days in culture, upon reaching 90% confluence, cells were split 1:4, using TripLE (Invitrogen). The cells were cultured for at least 8 passages.
PSC- and lineage converted-CD34+ cells, isolated by MACS or by FACS sorting after 8 days of differentiation in MIM, were plated in collagen I coated plates (50,000 cells well−1 of a 12-well plate) and cultured in SmBM/SmGM-2 (Lonza) with media changes every day. After 5–8 days in culture, upon reaching 90% confluence, cells were split 1:4, using TripLE (Invitrogen). The cells were cultured for at least 8 passages.
Illumina 450K Infinium Methylation Arrays were normalized and pre-processed in Genome Studio. Probes with missing values were removed. A filter for average Beta value difference between groups (PSCs, Fibroblasts, primary human Arterial Smooth Muscle Cells (PriSMC), primary human Umbilical Vein Endothelial Cells (PriEC), PSC → CD34+ Progenitor Cells, PSC → Endothelial Cells (iECs), converted Endothelial Cells (cECs), PSC → Smooth Muscle Cells (iSMCs), converted Smooth Muscle Cells (cSMCs)) of ≥0.3 was applied. The resulting probes were used for ANOVA analysis using R scripts with a p-value filter of <0.0001)(at this point, 30,000 probes remained). Probes with beta value difference of at least 0.3 ((max - min) >= 0.3) were used. ANOVA test (p<0.05; Var 0.58) was applied to obtain statistically significant differentially methylated probes among the 5 groups in both SMC and EC sample group. The resulting probes (see Supplementary Data) were used for hierarchical clustering using Cluster 3.0 with complete linkage. Venn Diagram Plotter (http://omics.pnl.gov/software/VennDiagramPlotter.php) was used to generate “area-proportional Venn Diagrams”.
The following groups were analyzed: PSCs, Fibroblasts, primary human Arterial Smooth Muscle Cells (PriSMC), primary human Umbilical Vein Endothelial Cells (PriEC), PSC → Endothelial Cells (iECs), converted Endothelial Cells (cECs), PSC → Smooth Muscle Cells (iSMCs) and converted Smooth Muscle Cells (cSMCs). Briefly, total RNA was extracted from collected sample pellets (Ambion mirVana; Applied Biosystems) according to the manufacturer’s protocol. RNA quantity (Qubit™ RNA BR Assay Kits; Invitrogen) and quality (RNA6000 Nano Kit; Agilent) was determined to be optimal for each sample prior to further processing. 200ng RNA per sample was amplified using the Illumina® Total Prep™ RNA Amplification Kit according to manufacturer’s protocol and quantified as above. 750ng RNA/sample was hybridized to Illumina HT-12v3 Expression BeadChips, scanned with an Illumina iScan Bead Array Scanner and quality controlled in GenomeStudio and the lumi bioconductor package. All RNA processing and microarray hybridizations were performed in-house according to manufacturer’s protocols. Differential expression was defined as a minimum 2x fold-change and multiple-testing corrected p<0.05 by ANOVA. The resulting probes (see Supplementary Data) were used for hierarchical clustering using Cluster 3.0 with complete linkage. Probes with minimum gene expression differences between groups of 2× fold-change were obtained (see Supplementary Data). Venn Diagram Plotter (http://omics.pnl.gov/software/VennDiagramPlotter.php) was used to generate “area-proportional Venn Diagrams”.
Briefly, total DNA was extracted using the Qiagen DNeasy Blood & Tissue kit (QIAGEN). The purity and quantity of DNA was measured using a NanoDrop 8000 spectrophotometer (Thermo Scientific), and then used as templates for absolute quantitation by qPCR assay22. The primers used are listed above and their amplification efficiencies, as well as specificity, were checked by performing standard curve and melting curve analyses.
Briefly, cells were washed thrice with PBS and fixed using 4% PFA in 1X PBS. After fixation, cells were blocked and permeabilized for 1 hour at 37° C with 5% BSA/5% appropriate serum/1X PBS in the presence of 0.1% Triton X100. Subsequently, cells were incubated with the indicated primary antibody either for 1 hour at room temperature or overnight at 4° C. The cells were then washed thrice with 1X PBS and incubated for 1 hour at 37° C with the respective secondary antibodies and 20 minutes with DAPI or Hoechst 33342. Cells were washed thrice with 1X PBS before analysis. Sections were analyzed by using an Olympus 1X51 upright microscope equipped with epifluorescence and TRITC, FITC, and DAPI filters. Confocal image acquisition was performed using a Zeiss LSM 780 laser scanning microscope (Carl Zeiss Jena, Germany) with 20×, 40× or 63× immersion objectives.
In short, 80% confluent endothelial cells derived from human ES/iPS cells were incubated with 10μg ml−1 Dil-Ac-LDL (L23380, Molecular Probes) for 3 hours in DMEM:F12. The cells were washed 3 times with PBS, dissociated using TripLE and analyzed by flow cytometry. Briefly, to assess the formation of capillary structures, a suspension of 4.105 cells ml−1 endothelial cells in the presence EBM-2/EGM-2 was prepared. Subsequently, 100 μl well−1 were dispensed on flat bottom 96 well plates coated with Matrigel (BD biosciences). Tube formation was observed after 24 hours of incubation and a minimum of three replicates per experiment analyzed.
Hematopoietic clonogenic assays were performed in 35-mm low adherent plastic dishes (Stem Cell Technologies, Vancouver, BC, Canada) using 1.1 ml dish−1 of methylcellulose semisolid medium (MethoCult H4434 classic, Stem Cell Technologies) according to the manufacturer’s instructions. Briefly, enriched CD34+ cells were sorted and immediately plated at various densities: 1.5 × 103 ml−1, 3 × 103 ml−1 and 6 × 103 ml−1. All assays were performed in duplicate. After 21 days of incubation plates were analyzed for the presence of both, Colony-forming units (CFU) and Burst-forming units (BFU).
All murine experiments were conducted with approval of The Salk Institute Institutional Animal Care and Use Committee (IACUC). NOD.Cg-PrkdcscidIl2rgtm1Wjl/SzJ mice (or NOD-Scid IL2rγ null abbreviated as NSG; age, 7 weeks; weight, 20 g) were purchased from Charles River Laboratories, housed in air-flow racks on a restricted access area and maintained on a 12 hour light/dark cycle at a constant temperature (22 ±1°C).
Anaesthesia was induced using a mixture of Xylazine (Rompun® 2%, Bayer) at 10 mg kg−1 and Ketamine (Imalgene1000, Merial) at 100 mg kg−1 in NaCl at 0.9% i.p injected at a dose of 10 ml kg−1. The animals’ backs were shaved, swabbed with Hexomedine®. Prior injection, HUVECs, HUES9-, KiPS-, BJ 6F- and BJ 6F/miRs- derived endothelial cells were harvested using TripLE (invitrogen). A total of 1.106 cells were resuspended in 500 μl of cold matrigel (Matrigel basement membrane matrix from BD Biosciences adjusted to 9.8 mg ml−1 PBS) supplemented with 150 ng of bFGF. Cell and no cell containing matrigel solutions were then injected subcutaneously in the back of mice, carefully positioning the needle between the epidermis and the muscle layer. Seventeen days later, mice were sacrificed and the matrigel plugs were removed by a wide excision of the back skin, including the connective tissues (skin and all muscle layers).
For immunohistochemistry (IHC), in situ hybridization (ISH) or immunofluorescence (IF) analysis, cell-containing implants with associated connective tissues were fixed with Accustain® (SIGMA) for 24 hours, dehydrated through an ethanol series and then processed for paraffin embedding before being sliced with a microtome. Slices from paraffin-embedded samples were stained with appropriate antibodies or probes. Alternatively, plugs were harvested and fixed with a 4% paraformaldehyde solution overnight at 4°, washed thrice in PBS and then incubated in a glucose solution (30%) for another 48 hours before being sliced (45μm) with a cryostat (Leica). Both methodologies were equally successful to identify neovasculature derived from human cells.
For IHC, slides were stained with an anti human-CD31 monoclonal antibody and then incubated with biotin-labeled secondary antibody followed by incubation with streptavidin-HRP (Ventana Roche).
For ISH, slides were hybridized according to the manufacturer’s protocol with an Alu probe (780–2845, Ventana Roche) and then labeled with the ISH iView Blue Detection kit (760–092, Ventana Roche).
For IHC and ISH, images were then captured with a camera mounted on a light microscope (Nikon E-800).
For immunofluorescence assays, slides were stained with either rhodamine-labeled Ulex Europaeus Agglutinin I (UEA I, a marker for human endothelial cells from Vector Laboratories) or PECAM-1 (M-20) (CD31; sc1506, Santa Cruz Biotechnology) and anti-Human Nuclei 1:100 (MAB1281, Millipore) counterstained with DAPI. Images were captured with confocal microscopes (Zeiss, LSM 510 or LSM780).
Subconfluent cells were washed with DMEM:F12 and incubated for 45 minutes with 1 μM Fluo-4/AM (Molecular Probes) in 0.5% BSA, DMEM:F12 in an incubator at 37 °C, 95% CO2. After washing to remove unloaded dye, cells responses to 100 μM carbachol or vehicle (water) were imaged in HEPES-buffered, phenol red-free DMEM:F12 in a wide field fluorescent microscope (Olympus BX61WI) equipped for fast fluorescent imaging. Image capture was performed with Metamorph and an EM-CCD camera (Hamamatsu). Image analysis was carried out with Metamorph and Fiji software. To determine functional SMC contraction after stimulations, the cell surface area was determined before and after carbachol exposure.
Statistical analyses of all endpoints were performed by using standard unpaired Student t test (one-tailed, 95% confidence intervals) using the SPSS/PC + statistics 11.0 software (SPSS Inc.). All data are presented as mean ± standard deviation (s.d.) or standard error of the mean (s.e.m.) where indicated and represent a minimum of two independent experiments with at least two technical duplicates.
L.K., I.S.M., E.N. and J.C.I.B. designed all experiments. I.S.M., E.N. and J.C.I.B. wrote the manuscript. L.K., I.S.M., K.M., E.N. and A.A. performed and analyzed all experiments. C.P., C.V.C., F.B., E.N., I.D. and J.M.H. performed in vivo experiments. K.M. was responsible for all cell culture related work. M.L., A.M.D. and F.H.G. provided miRNA constructs and reagents. J.P., Y.X., S.R., I.D., N.M., C.R., A.M.D., and F.H.G. contributed to the overall design of the project. F.S.B., R.D.T., J.F.L. and L.C.L. performed and analyzed genome-wide array DNA methylation and gene-expression studies.
We are thankful to Y. Zheng for his expertise and assistance with sorting procedures. We thank C. Maiza for his expertise and assistance with in vivo procedures. We thank M. Schwarz for administrative support. L.K. was partially supported by the California Institute for Regenerative Medicine. E.N. was partially supported by a F.M. Kirby Foundation postdoctoral fellowship. A.M.D. was supported by the Helmsley Foundation. L.C.L., R.D.T., F.S.B. and J.F.L. are supported by the California Institute for Regenerative Medicine (CL1-00502, RT1-01108, TR1-01250, RN2-00931), National Institutes of Health (R33MH087925), National Institutes of Health/National Institute Child Health and Human Development K12 Career Development Award (L.C.L.), the Hartwell Foundation (L.C.L., R.D.T., F.S.B.), the Millipore Foundation (J.F.L.), and the Esther O’Keefe Foundation (J.F.L.). Work in the laboratory of J.C.I.B. was supported by grants from Fundacion Cellex, the G. Harold and Leila Y. Mathers Charitable Foundation, The Leona M. and Harry B. Helmsley Charitable Trust, Sanofi and Ministerio de Economia y Competitividad.
|1.||Sancho-Martinez I,Nivet E,Izpisua Belmonte JC. The labyrinth of nuclear reprogrammingJ Mol Cell Biol3327329Year: 201122090451|
|2.||Takahashi K,Yamanaka S. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factorsCell126663676Year: 200616904174|
|3.||Laiosa CV,Stadtfeld M,Xie H,de Andres-Aguayo L,Graf T. Reprogramming of committed T cell progenitors to macrophages and dendritic cells by C/EBP alpha and PU.1 transcription factorsImmunity25731744Year: 200617088084|
|4.||Ieda M,et al. Direct reprogramming of fibroblasts into functional cardiomyocytes by defined factorsCell142375386Year: 201020691899|
|5.||Vierbuchen T,et al. Direct conversion of fibroblasts to functional neurons by defined factorsNature46310351041Year: 201020107439|
|6.||Vierbuchen T,Wernig M. Direct lineage conversions: unnatural but useful?Nat Biotechnol29892907Year: 201121997635|
|7.||Efe JA,et al. Conversion of mouse fibroblasts into cardiomyocytes using a direct reprogramming strategyNat Cell Biol13215222Year: 201121278734|
|8.||Kim J,et al. Direct reprogramming of mouse fibroblasts to neural progenitorsProc Natl Acad Sci U S A10878387843Year: 201121521790|
|9.||Sancho-Martinez I,Baek SH,Izpisua Belmonte JC. Lineage conversion methodologies meet the reprogramming toolboxNat Cell Biol14892899Year: 201222945254|
|10.||Papp B,Plath K. Reprogramming to pluripotency: stepwise resetting of the epigenetic landscapeCell Res21486501Year: 201121321600|
|11.||Plath K,Lowry WE. Progress in understanding reprogramming to the induced pluripotent stateNat Rev Genet12253265Year: 201121415849|
|12.||Goldman O,et al. A boost of BMP4 accelerates the commitment of human embryonic stem cells to the endothelial lineageStem Cells2717501759Year: 200919544443|
|13.||Dzierzak E,Speck NA. Of lineage and legacy: the development of mammalian hematopoietic stem cellsNat Immunol9129136Year: 200818204427|
|14.||Choi KD,et al. Hematopoietic and endothelial differentiation of human induced pluripotent stem cellsStem Cells27559567Year: 200919259936|
|15.||James D,et al. Expansion and maintenance of human embryonic stem cell-derived endothelial cells by TGFbeta inhibition is Id1 dependentNat Biotechnol28161166Year: 201020081865|
|16.||Levenberg S,Ferreira LS,Chen-Konak L,Kraehenbuehl TP,Langer R. Isolation, differentiation and characterization of vascular cells derived from human embryonic stem cellsNat Protoc511151126Year: 201020539287|
|17.||Anokye-Danso F,et al. Highly efficient miRNA-mediated reprogramming of mouse and human somatic cells to pluripotencyCell Stem Cell8376388Year: 201121474102|
|18.||Subramanyam D,et al. Multiple targets of miR-302 and miR-372 promote reprogramming of human fibroblasts to induced pluripotent stem cellsNat Biotechnol29443448Year: 201121490602|
|19.||Narazaki G,et al. Directed and systematic differentiation of cardiovascular cells from mouse induced pluripotent stem cellsCirculation118498506Year: 200818625891|
|20.||Cheung C,Bernardo AS,Trotter MW,Pedersen RA,Sinha S. Generation of human vascular smooth muscle subtypes provides insight into embryological origin-dependent disease susceptibilityNat Biotechnol30165173Year: 201222252507|
|21.||Chan EM,et al. Live cell imaging distinguishes bona fide human iPS cells from partially reprogrammed cellsNat Biotechnol2710331037Year: 200919826408|
|22.||Okita K,et al. A more efficient method to generate integration-free human iPS cellsNat Methods8409412Year: 201121460823|
|23.||Ohta T,Ito S,Nakazato Y. All-or-nothing responses to carbachol in single intestinal smooth muscle cells of ratBr J Pharmacol112972976Year: 19947921627|
|24.||Kohda M,Komori S,Unno T,Ohashi H. Carbachol-induced [Ca2+]i oscillations in single smooth muscle cells of guinea-pig ileumJ Physiol492 Pt 2315328Year: 19969019532|
|25.||Yamanaka S. Induced pluripotent stem cells: past, present, and futureCell Stem Cell10678684Year: 201222704507|
|26.||Yusa K,et al. Targeted gene correction of alpha1-antitrypsin deficiency in induced pluripotent stem cellsNature478391394Year: 201121993621|
|27.||Giorgetti A,et al. Generation of induced pluripotent stem cells from human cord blood using OCT4 and SOX2Cell Stem Cell5353357Year: 200919796614|
|28.||Aasen T,et al. Efficient and rapid generation of induced pluripotent stem cells from human keratinocytesNat Biotechnol2612761284Year: 200818931654|
|29.||Ludwig TE,et al. Derivation of human embryonic stem cells in defined conditionsNat Biotechnol24185187Year: 200616388305|
Previous Document: JAABA: interactive machine learning for automatic annotation of animal behavior.
Next Document: Quality-filtering vastly improves diversity estimates from Illumina amplicon sequencing.